RxDoctor Payments DataLook up a doctor →

Winston Chua, MD

Hematology & Oncology · Paducah, KYNPI 1013923846

Payments from drug & device makers

$66,308in general payments, 2019–2025

Across 309 payments — averaging $214.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$39K
  • E.r. Squibb & Sons, L.L.C.$17K
  • Novartis$6K
  • Pfizer$456
  • Johnson & Johnson$407
  • Merck$361
  • plus $3K from 46 others

What the payments were for

  • Food & beverage$4,74595%
  • Education$2435%
  • Gifts$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$66,308 in reported general payments places this provider in the 65th percentile of 143 hematology & oncology providers in Kentucky.

See all hematology & oncology providers in Kentucky

Medicare billing

Part B allowed, 2024
$175,794
Medicare patients
355
Services billed
1,361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib38$440,606
CabometyxCabozantinib S-Malate18$423,439
BrukinsaZanubrutinib26$354,415
Abiraterone Acetate82$317,788
KisqaliRibociclib Succinate22$294,000
Lenalidomide18$204,318
IbrancePalbociclib12$195,621
VerzenioAbemaciclib13$188,258
ErleadaApalutamide12$171,558
CalquenceAcalabrutinib Maleate12$166,129
RetacritEpoetin Alfa-Epbx13$22,484
XareltoRivaroxaban27$21,694
EliquisApixaban30$20,497
Everolimus16$20,315
Ondansetron Hcl102$16,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$118$440,60638 claims
Exelixis Inc.Cabometyx$78$423,43918 claims
Beigene USA, Inc.Brukinsa$21$354,41526 claims
NovartisKisqali$6,165$294,00022 claims
PfizerIbrance, Retacrit, Eliquis$456$238,60155 claims
Johnson & JohnsonErleada, Xarelto$407$193,25239 claims
Lilly USA, LLCVerzenio$161$188,25813 claims
AstraZenecaCalquence$38,964$166,12912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 143 hematology & oncology providers in Kentucky.

Other hematology & oncology in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →